Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study-Reference-Cited by-同舟云学术

Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study

Published:2019-11-06 Issue:1 Volume:9 Page:12-18
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Lei Lei¹^ORCID,Wang Wen‐xian¹^ORCID,Zhu You‐cai²,Li Jin‐luan³^ORCID,Fang Yong⁴,Wang Hong⁵,Zhuang Wu⁶,Zhang Yin‐bin⁷,Wang Li‐ping⁸,Fang Mei‐yu¹,Xu Chun‐wei⁹^ORCID,Wang Xiao‐jia¹,Lv Tang‐feng¹⁰,Song Yong¹⁰^ORCID

Affiliation:

1. Department of Medical Oncology Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Hangzhou Zhejiang People's Republic of China

2. Department of Thoracic Disease Center Zhejiang Rongjun Hospital Jiaxing Zhejiang People's Republic of China

3. Department of Radiotherapy Xiamen Cancer Hospital The First Affiliated Hospital of Xiamen University Xiamen Fujian People's Republic of China

4. Department of Oncology Sir Run Run Shaw Hospital Hangzhou Zhejiang People's Republic of China

5. Department of Lung Cancer The Fifth Medical Center General of PLA Beijing People's Republic of China

6. Department of Medical Oncology Fujian Provincial Cancer Hospital Fujian Medical University Cancer Hospital Fuzhou Fujian People's Republic of China

7. Department of Oncology The Second Affiliated Hospital of Medical College Xi′an Jiaotong University Xi'an Shaanxi People's Republic of China

8. Department of Oncology Baotou Cancer Hospital Baotou Inner Mongolia People's Republic of China

9. Department of Pathology Fujian Cancer Hospital Fujian Medical University Cancer Hospital Fuzhou Fujian People's Republic of China

10. Department of Respiratory Medicine Jinling Hospital Nanjing Jiangsu People's Republic of China

Funder

Xisike-Hanson Cancer Research Foundation

Medical Scientific Research Foundation of Zhejiang Province

Zhejiang Province Science and Technology Project of Traditional Chinese Medicine

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2652

Reference31 articles.

1. Metastatic non‐small‐cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up;Siegel RL;Ann Oncol,2010

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

3. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

4. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib

5. Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi‐center study;Cancer Science;2023-03-12

2. Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?;Journal of Clinical Medicine;2023-02-10

3. Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes;Cancer Epidemiology;2022-02

4. Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence;Current Oncology;2022-01-09

5. Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations;Thoracic Cancer;2021-09-21